The medication is applied when supportive symptom management is appropriate in clinical settings marked by increased discomfort and tension. Documented in literature where it is medically used, it is relevant for conditions involving manifestations such as anxiety, asthenia (chronic fatigue/weakness), sleep disturbances, and vestibular disorders. It is commonly used across conditions presenting with acute episodes, applied in clinical settings that involve acute or unstable symptom patterns, such as during pre-operative phases or alcohol withdrawal.

The medication helps address symptom clusters that may become intense or disruptive, such as inner tension, chronic irritation, and debilitating physical fatigue. This symptomatic support contributes to improved comfort during periods of heightened symptoms, and may help patients cope more steadily with symptom fluctuations.

“It is applied when symptoms create noticeable functional strain, assisting with maintaining functional stability.”

---

Quick Fact: Relief for Neurotic Tension

Focus Area	Symptom Relief Provided
Primary Use	Easing inner tension, anxiety, and general nervous restlessness.
Secondary Use	Managing chronic fatigue, sleep difficulties, and dizziness/unsteadiness.
Key Benefit	Helps ease the overall symptom load and distress.

Regulatory References

1. World Health Organization (WHO) Pre-Review Report on Phenibut

The official regulatory profile for Фенибут (Aminophenylbutyric acid) establishes clear boundaries defining eligible and restricted populations, based strictly on prescribing information.

Eligibility Scope

Eligibility scope	Status according to Regulatory Labeling
Populations for whom use is allowed	Adults and the pediatric population from 3 years of age.
Populations for whom use is contraindicated	Acute renal insufficiency, pregnancy, lactation, and known hypersensitivity to the drug substance or excipients like lactose.
Age-related eligibility rules	Use is strictly contraindicated in children under 3 years old. Older adults are permitted, but are subject to a lower maximum single-dose limitation.
Condition-specific eligibility rules	Use requires caution in patients with hepatic insufficiency and those with erosive and ulcerative lesions of the gastrointestinal tract.
Pregnancy and lactation eligibility status	Contraindicated.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): The two primary classifications used are Contraindication (absolute prohibition) and Use with Caution (conditional restriction/limitation).

Eligibility-context constraints (as defined in official documents): Constraints are defined by specific Age thresholds, Physiological State (pregnancy/lactation), and underlying Comorbidities (acute renal failure, hepatic insufficiency).

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with acute kidney failure, pregnancy, and lactation.
• Use is contraindicated for children under the age of 3 years.
• Caution is mandatory for patients with hepatic insufficiency, often requiring liver function monitoring.

Connection to the overall eligibility profile: Official prescribing information strictly defines who can and cannot use the medicine by establishing absolute prohibitions based on acute physiological status and intolerance, classifying them as contraindicated. Populations that are otherwise permitted, such as those with hepatic impairment or older adults, are subject to explicit limitations documented in the label.

Interactions with other medicines and products

The official regulatory profile of Aminophenylbutyric acid (Фенибут) focuses on significant pharmacodynamic interactions stemming from its Central Nervous System (CNS) depressant properties. All formal statements regarding co-administration are based on the risk of mutual reinforcement of CNS effects.

Interaction Scope

Element	Official Regulatory Documentation
Medicinal Product Categories	Co-administration with other CNS Depressants leads to mutual potentiation and an extension of the duration of their effects.
Classes of Concern	This pharmacodynamic interaction applies to product classes such as Anxiolytics, Antipsychotics, Sedatives/Hypnotics, Opioids, and Anticonvulsants.
Mechanistic Basis	The primary documented mechanism is pharmacodynamic reinforcement of CNS depressant activity.
Alcohol Interaction	Co-ingestion with Alcohol (Ethanol) is explicitly documented as leading to a strong potentiation of psychoactive effects.

Interaction Structure

Classification Element	Official Regulatory Documentation
Interaction Severity	Interactions are formally noted as carrying an increased risk of severe adverse outcomes, including profound oversedation and respiratory depression.
Restrictions	Specific warnings exist regarding the combination with alcohol due to its association with major toxicity.

The regulatory documentation defines the product's interaction structure by highlighting the potential for mutual reinforcement with various CNS-acting drug categories. Official statements emphasize the resulting risks of oversedation and respiratory depression, which require careful consideration by prescribing professionals.

Agonism at the Inhibitory GABAB Receptor

The drug's primary action involves acting as an agonist at the GABAB receptors found within the central nervous system. This molecular interaction mimics the body's primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), initiating signaling sequences that lead to the hyperpolarization of nerve cells. This contributes to a reduction in the overall excitability of the central nervous system, leading to the physiological consequence of diminished arousal.

---

Modulation of Presynaptic Calcium Channels

A key secondary mechanism involves the drug's binding and inhibition of the alpha2 delta subunits of voltage-dependent calcium channels (VDCCs) located on presynaptic nerve terminals. By reducing the influx of calcium ions, the drug limits the release of various excitatory neurotransmitters into the synapse. This action modulates the dynamics of processes driven by excessive excitatory signaling and contributes to reduced skeletal muscle tone.

---

Influence on Trace Amine Pathways

The drug also modifies mechanisms that influence activity in other neurochemical pathways. It acts as an antagonist to the trace amine beta-phenethylamine, and also interacts with dopaminergic pathways. This activity modulates pathways associated with central arousal, influencing the state of these systems and contributing to the diminution of heightened sensory input.

How to Use Aminophenylbutyric Acid: Official Guidelines

Aminophenylbutyric acid (Phenibut) is administered orally (per os) as tablets. The administration protocol is explicitly defined in official documentation, providing clear instructions for dosing, frequency, and course duration.

---

Official Dosing and Scheduling

The standard single dose for adults typically ranges from 250 mg to 500 mg, generally taken three times per day. The maximum allowed single dose for the general adult population is 750 mg. For older adults (60 years), the maximum single dose is 500 mg. The treatment is generally recommended to be taken after meals.

For children aged 8–14, the official schedule is 250 mg per dose, administered three times daily. For prophylactic use, such as preventing motion sickness, a single dose of 250 mg to 500 mg is taken approximately one hour prior to the event.

---

Course Duration and Procedural Requirements

A typical course of treatment lasts 2 to 3 weeks, though the duration may be extended up to a maximum of 4 to 6 weeks when clinically appropriate. The official instructions mandate that if the treatment course exceeds 2 to 3 weeks, specific monitoring of peripheral blood composition and liver function indices is required.

The tablets must be swallowed whole (do not chew). When this medicine is administered concurrently with other psychotropic agents, the dose of both medications must be reduced to adhere to the official use protocol.

Research evidence / Overview of studies for Фенибут

Evidence for Use in Symptoms of Tension and Anxiety

Research has often explored Aminophenylbutyric acid in the context of studies examining patient-reported experiences of anxiety and tension. This research base includes both Randomized Controlled Trials (RCTs) and open-label controlled trials, where scientists examined how symptoms changed over defined time intervals. These studies primarily included adult populations who were experiencing conditions characterized by fluctuating or episodic manifestations such as inner tension or fear.

In these trials, researchers measured outcomes related to perceived discomfort using standardized scales for anxiety and also assessed the quality of sleep. Findings from these clinical studies describe patterns observed in the studies related to the way patients reported their anxiety scores during the short-term period. The certainty surrounding these findings is limited by research limitations, as a significant portion of the primary data was observed in some studies that were open-label.

Evidence for Use in Asthenia and Chronic Weakness

Aminophenylbutyric acid was evaluated in research exploring symptom changes related to asthenia, or chronic weakness. This evidence was derived from settings involving varying symptom burdens and includes open-label controlled trials that examined outcomes related to systemic or functional imbalance. The studied populations were generally adults presenting with significant fatigue. The research described observations regarding changes in patient-reported outcomes over the short term. However, the evidence supporting this area is limited due to modest sample sizes and the prevalence of open-label designs.

Limitations and Research Uncertainty

A significant feature of the existing evidence landscape is the level of uncertainty. For several studied indications, comparative evidence is lacking, meaning few high-quality trials have directly compared Aminophenylbutyric acid against other treatments. The evidence quality varies across studies, leading to overall low or moderate certainty in the scientific community. Furthermore, long-term effects are not fully established, as clinical research focuses mainly on observation periods of up to approximately three months.

Key Studies & References World Health Organization (WHO) Pre-Review Report on Phenibut: 44th Expert Committee on Drug Dependence (ECDD)

Common questions about Фенибут (FAQ)

Q: Is Фенибут a controlled substance or prescription-only in most countries?

In jurisdictions where this medicine is officially licensed for use, it is generally available by prescription only. It is important to know that in many major countries, including the United States and most of the European Union, the drug is not approved for medical use. The specific legal status or classification can vary significantly depending on the national drug control policies of each country.

Q: How long does it typically take to feel the effects after taking Фенибут?

Pharmacokinetic data from regulatory and medical reviews suggest that the effects following oral administration are generally observed within approximately two to four hours. This time frame reflects when the compound begins to be absorbed and distributed to the central nervous system.

Q: Can Фенибут be used for generalized anxiety, or is it only for specific conditions?

Official prescribing information from licensed regions lists the use of the medicine for conditions such as anxiety, tension, and neurosis. The regulatory documents do not specifically name or exclude a formal diagnosis like Generalized Anxiety Disorder (GAD), but they outline its approved uses for managing these general symptoms.

Q: Do studies suggest Фенибут is more for short-term or long-term use?

Official guidelines define a maximum course duration, typically limited to four to six weeks. Clinical research observations mainly focus on short-term effects over periods of up to three months. Information regarding long-term effects beyond the studied periods is considered not fully established.

Q: Can people who work in demanding, focus-required jobs use Фенибут?

Official safety information lists somnolence (drowsiness) and dizziness as common adverse effects. Warnings related to Central Nervous System (CNS) depression and potential motor incoordination indicate that the presence of these effects requires careful consideration, especially regarding activities such as operating heavy machinery.

Q: Does official information about Фенибут mention anything about changes in mood or personality?

The official safety profile and case reports mention adverse effects such as agitation, irritability, and euphoria during use, which are states related to mood. Changes in anxiety or depression may also be observed during the cessation period.

Q: Can Фенибут affect the results of other medical tests?

Official guidelines specify that if the course of treatment exceeds two to three weeks, specific monitoring of peripheral blood composition and liver function indices is required. The requirement for monitoring suggests that the prescribing professional is considering the potential for the drug to influence the results of these tests.

Q: Is there any evidence suggesting Фенибут can affect physical coordination?

Official documents and safety reviews list potential adverse effects related to the nervous system, including dizziness, loss of balance, and motor incoordination, particularly when higher doses are used.

Q: What is the typical duration of effect reported for one dose of Фенибут?

Pharmacokinetic data available in some reviews indicate that the duration of effects from a single dose may range from 15 to 24 hours. This duration is distinct from the drug's half-life (the time it takes for half of the drug to be eliminated from the body).

Q: Is there a known rebound anxiety effect after stopping Фенибут?

The official safety profile notes the potential for Tolerance and Dependence with prolonged use. Withdrawal symptoms associated with cessation may include heightened anxiety, agitation, and other neuro-psychiatric effects, particularly following prolonged use.

Q: What does 'unlicensed' or 'off-label' use of Фенибут mean, legally?

A drug is considered unlicensed in countries where it has not received authorization for medical use from the national regulatory body, such as the FDA or EMA. Off-label use refers to the use of an approved medicine for a condition, population, or dosage not specified in its official prescribing information.

Q: Can using Фенибут cause a feeling of 'mental fog' or difficulty concentrating?

Official safety information lists somnolence (drowsiness) and dizziness as common side effects. Additionally, reports of withdrawal symptoms have included 'cognitive deficits' or difficulty focusing upon cessation.

Q: Does the efficacy of Фенибут change over time with continued use?

Official safety documentation notes the potential for the development of Tolerance with repeated or prolonged use. The potential for tolerance suggests that the intended effectiveness of the drug may lessen over time.

Q: Are there any non-directive instructions about how to stop taking Фенибут?

Due to the potential for physical dependence and withdrawal symptoms after prolonged use, cessation is generally managed through a gradual reduction (tapering) process. The process of discontinuation is typically overseen by a prescribing professional.

Q: Can the official uses of Фенибут vary significantly between countries?

Yes. The official uses and licensing status vary internationally. The drug is licensed for specific medical conditions in certain countries, such as Russia and Ukraine, but remains unapproved for medical use in many other major global jurisdictions.

Q: Does taking Фенибут affect your appetite or weight?

Appetite and weight changes are not typically listed among the common adverse effects that occur during treatment. However, reports of symptoms following cessation have included issues such as decreased appetite, nausea, and vomiting.

Q: Are there any visual or perceptual side effects associated with Фенибут?

While not common side effects during regular use, reports have associated severe withdrawal syndromes with the potential for more pronounced central nervous system effects, including hallucinations (visual or auditory) and delirium.

Q: Is there guidance on managing minor, common side effects of Фенибут?

The most common side effects, such as somnolence, are noted in official documents to be more pronounced at the start of the course and during any increases in the dose. This suggests that these effects may diminish as the body adjusts to the medicine.

Q: What research exists regarding the safety of Фенибут during pregnancy?

According to the official prescribing information from jurisdictions where the drug is approved, use during pregnancy and lactation is contraindicated (absolutely prohibited). The specific research findings that informed this decision are not detailed in the patient information.

How to Store and Dispose of Phenibut (Фенибут)

Phenibut is not approved as a licensed prescription drug by major governmental regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Consequently, there are no official, standardized storage, handling, or disposal requirements documented in the prescribing information or Summary of Product Characteristics (SmPC) issued by these major global agencies.

Since it lacks regulatory approval as a drug in these jurisdictions, official documents do not define:

• Mandatory Storage Conditions: No labeled requirements for temperature, light, or moisture protection are established.
• Child-Protection Storage: No specific requirements regarding access for children are documented in official drug labeling.
• Official Disposal Instructions: The substance is not listed on recommended drug disposal lists, nor are specific disposal rules provided in official labeling.

Regulatory documentation contains no classifications for shelf-life, in-use stability, or specific handling instructions for this substance. Any storage or disposal must be guided by general safety practices for non-regulated substances, adhering to local waste management rules.